About Nkarta Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.nkartatx.com/
Frequently Asked Questions
What is the 52-week range for NKTX?
The 52-week high is $3.72 and the 52-week low is $1.7.
What is the P/E ratio for NKTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for NKTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -39.64%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.42.
Analyst Recommendation Trends
Wall Street analyst consensus for NKTX over the last few months:
Latest NKTX News
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogenei
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026H.C. Wainwright 28th Annual Global Investment Conference New York, NY10:30 a.m. ET – fireside chatSeptember 23, 2026Stifel 2026 Virtual Immunology and Inflammation Forum12:30 p.m. ET – f
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster presentation highlighting NKX019’s clinical activity in systemic sclerosis SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
Nkarta is pivoting its focus from r/r NHL to autoimmune disorders with its CD19 CAR-NK cell therapy, NKX019. Click here to read my most recent analysis.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J | -1,776 | $2.71 | $4,813 |
| 2026-06-10 | Vratsanos George | +37,000 | - | - |
| 2026-06-10 | Scheiner Zachary | +37,000 | - | - |
| 2026-06-10 | Thedinga Angela | +37,000 | - | - |
| 2026-06-10 | Behbahani Ali | +37,000 | - | - |
| 2026-06-10 | Dybbs Michael | +37,000 | - | - |
| 2026-06-10 | George Simeon | +37,000 | - | - |
| 2026-06-10 | RA Capital Healthcare Fund LP | +37,000 | - | - |
| 2026-06-10 | PATTERSON LEONE D | +37,000 | - | - |
| 2026-01-15 | Mahmood Nadir | -5,649 | $2.07 | $11,693 |
| 2026-01-15 | HASTINGS PAUL J | -26,046 | $2.07 | $53,915 |
| 2026-01-06 | Rose Shawn Marshall | +139,000 | - | - |
| 2026-01-06 | Rose Shawn Marshall | +70,000 | - | - |
| 2026-01-06 | Mahmood Nadir | +160,000 | - | - |
| 2026-01-06 | Mahmood Nadir | +80,000 | - | - |
| 2026-01-06 | HASTINGS PAUL J | +562,000 | - | - |
| 2026-01-06 | HASTINGS PAUL J | +94,000 | - | - |